165 related articles for article (PubMed ID: 37924330)
1. Diagnostic Outcomes of Concurrent DNA and RNA Sequencing in Individuals Undergoing Hereditary Cancer Testing.
Horton C; Hoang L; Zimmermann H; Young C; Grzybowski J; Durda K; Vuong H; Burks D; Cass A; LaDuca H; Richardson ME; Harrison S; Chao EC; Karam R
JAMA Oncol; 2024 Feb; 10(2):212-219. PubMed ID: 37924330
[TBL] [Abstract][Full Text] [Related]
2. Rates and Classification of Variants of Uncertain Significance in Hereditary Disease Genetic Testing.
Chen E; Facio FM; Aradhya KW; Rojahn S; Hatchell KE; Aguilar S; Ouyang K; Saitta S; Hanson-Kwan AK; Capurro NN; Takamine E; Jamuar SS; McKnight D; Johnson B; Aradhya S
JAMA Netw Open; 2023 Oct; 6(10):e2339571. PubMed ID: 37878314
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Diagnostic Outcomes of RNA Genetic Testing for Hereditary Cancer.
Karam R; Conner B; LaDuca H; McGoldrick K; Krempely K; Richardson ME; Zimmermann H; Gutierrez S; Reineke P; Hoang L; Allen K; Yussuf A; Farber-Katz S; Rana HQ; Culver S; Lee J; Nashed S; Toppmeyer D; Collins D; Haynes G; Pesaran T; Dolinsky JS; Tippin Davis B; Elliott A; Chao E
JAMA Netw Open; 2019 Oct; 2(10):e1913900. PubMed ID: 31642931
[TBL] [Abstract][Full Text] [Related]
4. Ethnic disparities among men with prostate cancer undergoing germline testing.
Kwon DH; Borno HT; Cheng HH; Zhou AY; Small EJ
Urol Oncol; 2020 Mar; 38(3):80.e1-80.e7. PubMed ID: 31630993
[TBL] [Abstract][Full Text] [Related]
5. Limited-Variant Screening vs Comprehensive Genetic Testing for Familial Hypercholesterolemia Diagnosis.
Sturm AC; Truty R; Callis TE; Aguilar S; Esplin ED; Garcia S; Haverfield EV; Morales A; Nussbaum RL; Rojahn S; Vatta M; Rader DJ
JAMA Cardiol; 2021 Aug; 6(8):902-909. PubMed ID: 34037665
[TBL] [Abstract][Full Text] [Related]
6. Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
Tsaousis GN; Papadopoulou E; Apessos A; Agiannitopoulos K; Pepe G; Kampouri S; Diamantopoulos N; Floros T; Iosifidou R; Katopodi O; Koumarianou A; Markopoulos C; Papazisis K; Venizelos V; Xanthakis I; Xepapadakis G; Banu E; Eniu DT; Negru S; Stanculeanu DL; Ungureanu A; Ozmen V; Tansan S; Tekinel M; Yalcin S; Nasioulas G
BMC Cancer; 2019 Jun; 19(1):535. PubMed ID: 31159747
[TBL] [Abstract][Full Text] [Related]
7. Inequities in multi-gene hereditary cancer testing: lower diagnostic yield and higher VUS rate in individuals who identify as Hispanic, African or Asian and Pacific Islander as compared to European.
Ndugga-Kabuye MK; Issaka RB
Fam Cancer; 2019 Oct; 18(4):465-469. PubMed ID: 31531760
[TBL] [Abstract][Full Text] [Related]
8. Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients.
Culver JO; Ricker CN; Bonner J; Kidd J; Sturgeon D; Hodan R; Kingham K; Lowstuter K; Chun NM; Lebensohn AP; Rowe-Teeter C; Levonian P; Partynski K; Lara-Otero K; Hong C; Morales Pichardo J; Mills MA; Brown K; Lerman C; Ladabaum U; McDonnell KJ; Ford JM; Gruber SB; Kurian AW; Idos GE
Cancer; 2021 Apr; 127(8):1275-1285. PubMed ID: 33320347
[TBL] [Abstract][Full Text] [Related]
9. Ancestry-specific hereditary cancer panel yields: Moving toward more personalized risk assessment.
Roberts ME; Susswein LR; Janice Cheng W; Carter NJ; Carter AC; Klein RT; Hruska KS; Marshall ML
J Genet Couns; 2020 Aug; 29(4):598-606. PubMed ID: 32227564
[TBL] [Abstract][Full Text] [Related]
10. Clinical Utility of Reinterpreting Previously Reported Genomic Epilepsy Test Results for Pediatric Patients.
SoRelle JA; Thodeson DM; Arnold S; Gotway G; Park JY
JAMA Pediatr; 2019 Jan; 173(1):e182302. PubMed ID: 30398534
[TBL] [Abstract][Full Text] [Related]
11. Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay.
Hu C; Susswein LR; Roberts ME; Yang H; Marshall ML; Hiraki S; Berkofsky-Fessler W; Gupta S; Shen W; Dunn CA; Huang H; Na J; Domchek SM; Yadav S; Monteiro ANA; Polley EC; Hart SN; Hruska KS; Couch FJ
Clin Cancer Res; 2022 Sep; 28(17):3742-3751. PubMed ID: 35736817
[TBL] [Abstract][Full Text] [Related]
12. Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.
Seifert BA; O'Daniel JM; Amin K; Marchuk DS; Patel NM; Parker JS; Hoyle AP; Mose LE; Marron A; Hayward MC; Bizon C; Wilhelmsen KC; Evans JP; Earp HS; Sharpless NE; Hayes DN; Berg JS
Clin Cancer Res; 2016 Aug; 22(16):4087-4094. PubMed ID: 27083775
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing.
Mersch J; Brown N; Pirzadeh-Miller S; Mundt E; Cox HC; Brown K; Aston M; Esterling L; Manley S; Ross T
JAMA; 2018 Sep; 320(12):1266-1274. PubMed ID: 30264118
[TBL] [Abstract][Full Text] [Related]
14. Germline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing.
Giri VN; Hartman R; Pritzlaff M; Horton C; Keith SW
JCO Precis Oncol; 2022 May; 6(1):e2200234. PubMed ID: 35666082
[TBL] [Abstract][Full Text] [Related]
15. Clinical Multigene Panel Testing Identifies Racial and Ethnic Differences in Germline Pathogenic Variants Among Patients With Early-Onset Colorectal Cancer.
Seagle HM; Keller SR; Tavtigian SV; Horton C; Holowatyj AN
J Clin Oncol; 2023 Sep; 41(26):4279-4289. PubMed ID: 37319387
[TBL] [Abstract][Full Text] [Related]
16. A multicenter study of clinical impact of variant of uncertain significance reclassification in breast, ovarian and colorectal cancer susceptibility genes.
Makhnoon S; Levin B; Ensinger M; Mattie K; Volk RJ; Zhao Z; Mendoza T; Shete S; Samiian L; Grana G; Grainger A; Arun B; Shirts BH; Peterson SK
Cancer Med; 2023 Feb; 12(3):2875-2884. PubMed ID: 36426404
[TBL] [Abstract][Full Text] [Related]
17. Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.
Chang J; Seng S; Yoo J; Equivel P; Lum SS
Ann Surg Oncol; 2019 Oct; 26(10):3389-3396. PubMed ID: 31342386
[TBL] [Abstract][Full Text] [Related]
18. Preconception carrier screening yield: effect of variants of unknown significance in partners of carriers with clinically significant variants.
Fridman H; Behar DM; Carmi S; Levy-Lahad E
Genet Med; 2020 Mar; 22(3):646-653. PubMed ID: 31624327
[TBL] [Abstract][Full Text] [Related]
19. Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.
Kurian AW; Ward KC; Hamilton AS; Deapen DM; Abrahamse P; Bondarenko I; Li Y; Hawley ST; Morrow M; Jagsi R; Katz SJ
JAMA Oncol; 2018 Aug; 4(8):1066-1072. PubMed ID: 29801090
[TBL] [Abstract][Full Text] [Related]
20. Insurance coverage does not predict outcomes of genetic testing: The search for meaning in payer decisions for germline cancer tests.
Amendola LM; Hart MR; Bennett RL; Horike-Pyne M; Dorschner M; Shirts B; Jarvik GP
J Genet Couns; 2019 Dec; 28(6):1208-1213. PubMed ID: 31317629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
